More than half of Phase 3 oncology trials fails.
Forward-looking predictions of Phase 3 success to identify high- and low-risk trials.
Overall accuracy of >70% enables applications in R&D portfolio management and capital allocation.
Research collaboration with Catenion, a strategy consultancy with the largest team exclusively focused on Biopharma R&D.
”Accurately translating expert judgement such as ‘strength of Phase 2 results’ in the design of unbiased quantative metrics is key to predictive power.”